Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07221981 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Patient With Frequent COPD Exacerbations

Study acronym: PRIORITY-COPD
StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary and study completion dates changed from estimate of Jun 30, 2026 to Jun 22, 2026 · Eligibility criteria expanded, about 9 words · Secondary endpoints: details revised at 11 of 28 entries · 1 more Show 4 more changesShow less
    • Primary and study completion dates changed from estimate of Jun 30, 2026 to Jun 22, 2026
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 11 of 28 entries
    • Site details revised at 1 of 6 sites
  2. Enrollment increased: 1708 → 2038 participantsv5
  3. Enrollment increased: 1519 → 1708 participantsv4
  4. Primary endpoints: 11 to 17 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 2000 to confirmed 1519 · Secondary endpoints: 16 to 28 · 1 morev3 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 2000 to confirmed 1519
    • Secondary endpoints: 16 to 28
    • Site details revised at 6 of 6 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
COPD
1,068 trials monitored
See 31 trials at risk
This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent exacerbations in the Russian Federation. Planned number of Study site is 35 outpatient centers with experience of treatment of COPD with frequency exacerbations in about 30 regions in Russia.
Trial Details
NCT Number NCT07221981
Lead Sponsor AstraZeneca
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 2,038 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov